


REMARKS

Entry of this amendment is respectfully requested. This Preliminary amendment is being filed in response to the Notice To File Corrected Application Papers mailed September 18, 2001, which indicated that an abstract was not provided for this application. By this amendment, applicants have added the Abstract at the end of the application. In addition, the Cross-reference to Related Application section has been added to the specification. Since no new matter has been added, entry of the amendment is respectfully requested.

Respectfully submitted,



Date: November 16, 2001

Peter J. Waibel, Reg. No. 43,228
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

09940963-112301